Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
Financial Associated Press, January 14 (Xinhua) the anti epidemic sector of Hong Kong stocks continued to rise, with Junshi biology up nearly 17%, kangxinuo biology up nearly 5%, Fosun Pharmaceutical up more than 4%, Geli pharmaceutical up nearly 4%, and stone pharmaceutical group up nearly 3%.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Apr 18, 2022 06:30 PM
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Briefing May 24, 2022 02:24 PM
· Healthcare
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
Briefing May 21, 2022 06:44 AM
· Financials
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Financials, Healthcare
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
See more
Read next
In-depth
Technology
Successful Multinational Corporations in China Series: Qualcomm China
Jun 25, 2022 02:02 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.